(Q38081238)

28 August 2017

title

Bevacizumab as front-line treatment for newly diagnosed epithelial cancer (English)

1 reference

28 August 2017

1 reference

Antonio González Martín

1

1 reference

28 August 2017

Raquel Bratos

2

1 reference

28 August 2017

Raúl Márquez

3

1 reference

28 August 2017

Sonsoles Alonso

4

1 reference

28 August 2017

Luis Chiva

5

1 reference

28 August 2017

publication date

1 February 2013

1 reference

Expert Review of Anticancer Therapy

28 August 2017

published in

1 reference

28 August 2017

volume

13

1 reference

28 August 2017

issue

2

1 reference

28 August 2017

page(s)

123-129

1 reference

28 August 2017

cites work

Cancer statistics, 2012

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.165

Variations in institutional infrastructure, physician specialization and experience, and outcome in ovarian cancer: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.165

2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.165

2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the Fourth Ovarian Cancer Consensus Conference

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.165

Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.165

Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.165

The addition of new drugs to standard therapy in the first-line treatment of ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.165

Intraperitoneal cisplatin and paclitaxel in ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.165

Intraperitoneal chemotherapy for optimally debulked advanced ovarian cancer: a new standard in patient care?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.165

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.165

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.165

Angiogenic mRNA and microRNA gene expression signature predicts a novel subtype of serous ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.165

Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.165

Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.165

Incorporation of bevacizumab in the primary treatment of ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.165

A phase 3 trial of bevacizumab in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.165

OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.165

Phase II study of intraperitoneal paclitaxel plus cisplatin and intravenous paclitaxel plus bevacizumab as adjuvant treatment of optimal stage II/III epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.165

21 January 2018

Identifiers

DOI

10.1586/ERA.12.165

1 reference

28 August 2017

1 reference